Editta Baldini

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations · Full text

Checkmate 063, Single-arm Trial, Medicine +8

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

Marcello Tiseo, Luca Boni, Francesca Ambrosio et al. · Journal of Clinical Oncology · 2017 · 182 citations

Cancer Management, Pathology, Arm B +17

Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial

Marco Venturini, Lucia Del Mastro, Enrico Aitini et al. · JNCI Journal of the National Cancer Institute · 2005 · 149 citations

Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis

Laura Boldrini, Silvia Gisfredi, Silvia Ursino et al. · Journal of Thoracic Oncology · 2007 · 100 citations · Full text

Molecular Diagnosis, Mutational Analysis, Cancer Pathology +11

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.

Pierfranco Conté, Editta Baldini, Alessandra Gennari et al. · Journal of Clinical Oncology · 1997 · 93 citations